Loading…
Based on XXX - Sodium butyrate + SoC & Inflammatory bowel disease (IBD), the oral intake of sodium butyrate (150 mg over 12 weeks) along with standard medication can significantly help children and adolescents newly diagnosed with inflammatory bowel diseases (IBD) - including Crohn's disease and ulcerative colitis. The inflammation is reduced. C-reactive protein (CRP) and fecal calprotectin as inflammation markers were significantly lower than in the placebo group. Remission rates (about 82%) are improved compared to placebo (about 48%) with good tolerability. The trial does not have an NCT code.
Butyrate / Butyric acid can be beneficial in the treatment of Crohn's disease and ulcerative colitis. Butyrate improves the integrity of the intestinal wall, making it less "permeable" and preventing harmful substances from entering the body through it. It reduces inflammation by influencing the immune system, increasing RAR-related Orphan Receptor Gamma/T (ROR-gamma/t) Isoform 2 (NR1F3)t+ Foxp3+ Colonic Treg cells, and suppressing certain pro-inflammatory cells and cytokines. Oral intake of butyrate or as part of fiber-rich diets can reduce intestinal inflammation and help maintain remission in IBD patients and animal models. Direct administration into the colon via enemas shows mixed results, with some studies reporting reduced inflammation, while others show little effect.
According to the study identified as NCT05456763, a 12-week course of sodium butyrate supplementation, when used as an adjunct therapy, did not prove to be effective for children and adolescents who were newly diagnosed with Inflammatory Bowel Disease (IBD).
see also:
Butyrate / Butyric acid & Regulatory T Cells (Tregs)
Histone H3
Inflammatory Bowel Disease (IBD) & Short-Chain Fatty Acids (SCFAs)
Pediatric Inflammatory Bowel Disease (IBD)